Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avigen
Drug developer to realign product development strategy
June 26th, 2004
Avigen (AVGN) announced that it will strategically refocus its research and drug development efforts. "The company has made a strategic decision to discontinue its current phase I trial for Coagulin-B and shift those resources into product candidates that more closely align with the company's new mission, in which it will expand and pursue its R & D efforts on serious and life threatening neurological disorders, including Parkinson's disease and chronic neuropathic pain," said Kenneth Chahine, Avigen's president and CEO. Chahine added, "While we are focusing on neurological disorders, we have every intention of preserving the large investment we have...
Source: Law & Health Weekly (2004-06-26)
|
